Ameriprise
CPRX

Ameriprise’s Catalyst Pharmaceutical CPRX Stock Holding History

Ameriprise’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.17M Buy
249,305
+33,383
+15% +$795K ﹤0.01% 2301
2025
Q4 		$5.04M Sell
215,922
-26,800
-11% -$597K ﹤0.01% 2430
2025
Q3 		$4.78M Sell
242,722
-7,427
-3% -$153K ﹤0.01% 2483
2025
Q2 		$5.43M Sell
250,149
-19,029
-7% -$449K ﹤0.01% 2293
2025
Q1 		$6.53M Sell
269,178
-13,656
-5% -$308K ﹤0.01% 2103
2024
Q4 		$5.9M Buy
282,834
+5,177
+2% +$111K ﹤0.01% 2247
2024
Q3 		$5.52M Sell
277,657
-39,318
-12% -$729K ﹤0.01% 2305
2024
Q2 		$4.91M Sell
316,975
-64,375
-17% -$1M ﹤0.01% 2329
2024
Q1 		$6.08M Sell
381,350
-70,885
-16% -$1.07M ﹤0.01% 2213
2023
Q4 		$7.6M Buy
452,235
+35,476
+9% +$485K ﹤0.01% 2017
2023
Q3 		$4.87M Sell
416,759
-20,209
-5% -$270K ﹤0.01% 2311
2023
Q2 		$5.87M Sell
436,968
-18,271
-4% -$263K ﹤0.01% 2219
2023
Q1 		$7.55M Sell
455,239
-181,502
-29% -$2.99M ﹤0.01% 1999
2022
Q4 		$11.8M Buy
636,741
+14,386
+2% +$221K ﹤0.01% 1605
2022
Q3 		$7.99M Buy
622,355
+414,034
+199% +$4.91M ﹤0.01% 1871
2022
Q2 		$1.46M Buy
208,321
+11,241
+6% +$82.4K ﹤0.01% 2952
2022
Q1 		$1.63M Sell
197,080
-341,779
-63% -$2.42M ﹤0.01% 3002
2021
Q4 		$3.65M Buy
538,859
+477,832
+783% +$3.14M ﹤0.01% 2679
2021
Q3 		$324K Buy
+61,027
New +$334K ﹤0.01% 3536
2021
Q2 		– Sell
-10,955
Closed -$50K – 3903
2021
Q1 		$50K Hold
10,955
– – ﹤0.01% 3801
2020
Q4 		$37K Sell
10,955
-17,911
-62% -$60.2K ﹤0.01% 3732
2020
Q3 		$86K Buy
28,866
+2,074
+8% +$8.11K ﹤0.01% 3652
2020
Q2 		$124K Buy
+26,792
New +$120K ﹤0.01% 3562
2018
Q1 		– Sell
-341,956
Closed -$1.34M – 3633
2017
Q4 		$1.34M Buy
+341,956
New +$1.13M ﹤0.01% 2851

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Ameriprise's CPRX Position: Q1 2026 in Review

Ameriprise increased its Catalyst Pharmaceutical (CPRX) stake by 15% in Q1 2026, buying an estimated $795K and bringing the position to 249,305 shares worth $6.17M. The position accounts for ﹤0.01% of the portfolio, ranked #2301.

Ameriprise first reported a position in CPRX in Q4 2017 and has held it in 24 quarters since. The position peaked at $11.8M in Q4 2022. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Ameriprise held 249,305 shares of Catalyst Pharmaceutical worth $6.17M as of Q1 2026.
  • Ameriprise bought 33,383 Catalyst Pharmaceutical shares in Q1 2026, an estimated $795K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #2301 holding.
  • Ameriprise first reported a position in Catalyst Pharmaceutical in Q4 2017 and has held it in 24 quarters since.
  • Ameriprise's Catalyst Pharmaceutical position peaked at $11.8M in Q4 2022.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.